Author

Jessica Caroprese

Observed name: J. Caroprese

Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence

Observed institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence

OpenAlex ID: A5093396812

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

2025 · Alessandro Vannucchi, Francesco Mannelli, et al. · Blood · 5

Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis

2025 · Francesca Crupi, Jessica Caroprese, et al. · Frontiers in Allergy · 2

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML

2025 · Francesco Mannelli, Matteo Piccini, et al. · Blood Cancer Journal · 2

Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report

2024 · Gaia Ciolli, Andrea Pasquini, et al. · Therapeutic Advances in Hematology · 2

APL-like Subset within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

2023 · Francesca Crupi, Gaia Ciolli, et al. · Blood · 2

Venetoclax and gilteritinib combination for FLT3-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience

2026 · Francesca Crupi, Gaia Ciolli, et al. · Haematologica · 1

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications

2026 · Francesco Mannelli, Francesca Crupi, et al. · HemaSphere · 1

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

2025 · Paola Guglielmelli, Francesca Crupi, et al. · Blood · 1

AML-558: Low Rate of Fungal Infections in a Population of Elderly/Unfit AML Patients Receiving Azacitidine and Venetoclax Without Posaconazole Prophylaxis: A Monocentric Experience

2025 · Matteo Piccini, Giorgio Cannetti, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

AML-555: MYC-Rearranged Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

2025 · Giorgio Cannetti, Barbara Scappini, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience

2026 · Gaia Ciolli, Matteo Piccini, et al. · Research Square

Clinical Experience With Venetoclax‐Based Combinations for Relapsed/Refractory or MRD ‐Positive NPM1 ‐Mutated Acute Myeloid Leukemia

2026 · Matteo Piccini, Naseema Gangat, et al. · American Journal of Hematology

POSTER: AML-558 Low Rate of Fungal Infections in a Population of Elderly/Unfit AML Patients Receiving Azacitidine and Venetoclax Without Posaconazole Prophylaxis: A Monocentric Experience

2025 · Matteo Piccini, Giorgio Cannetti, et al. · Clinical Lymphoma Myeloma & Leukemia

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

2024 · Gaia Ciolli, Matteo Piccini, et al. · Haematologica

Works count: 18

Citation count: 18

H-index: 2

I10-index: